ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CNTA Centessa Pharmaceuticals PLC

11.04
-0.36 (-3.16%)
10 Aug 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Centessa Pharmaceuticals PLC NASDAQ:CNTA NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.36 -3.16% 11.04 11.08 11.67 11.61 10.95 11.42 332,516 01:00:00

Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

01/09/2021 9:15pm

GlobeNewswire Inc.


Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart


From Aug 2021 to Aug 2024

Click Here for more Centessa Pharmaceuticals Charts.

Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, beginning at 5:00 p.m. Eastern Time.

A live audio webcast of this event can be accessed on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. Replay of the webcast will be archived on the Company's website for 90 days following the event.

About Centessa PharmaceuticalsCentessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa’s asset-centric companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. For more information, visit www.centessa.com.

Contacts:

Investor Contact:Media Contacts:
Jennifer Porcelli, Head of Investor RelationsUS
Centessa PharmaceuticalsDan Budwick, 1AB
jennifer.porcelli@centessa.comdan@1abmedia.com 
  
 UK/Greater Europe
 Mary Clark & Shabnam Bashir, Optimum Strategic Communications
 centessa@optimumcomms.com 
  
 Switzerland
 Marcus Veith, VEITHing Spirit
 marcus@vspirit.ch
 M: +41 79 20 75 111

1 Year Centessa Pharmaceuticals Chart

1 Year Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock